Statens Serum Institut - Recruiting N/A to 65 years. - A Phase III Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERONr-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI (PPD).
Statens Serum Institut - Recruiting 6 Weeks to 65 years. - A Phase III Contact Tracing Trial Comparing the Diagnostic Performance of C-Tb to QuantiFERONr-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI.
Dartmouth-Hitchcock Medical Center - Recruiting 18 years to 65 years. - A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Dose-Ranging Study of the Safety and Immunogenicity of DAR-901, a Killed, Non-Tuberculous Mycobacterial Vaccine, in HIV-negative and HIV-positive Adults Who Have Previously Received BCG.
Medical University of Warsaw - Recruiting 18 years to 80 years. - Diagnostic Accuracy of Different Bronchoscopic Sampling Techniques in Patients With Mediastinal Lymph Node Enlargement Suspected of Sarcoidosis.
EBUS guided transbronchial forceps biopsy (EBUS-TBFB); EBUS guided transbronchial needle aspiration (EBUS-TBNA); large bore (19G) histologic needle biopsy of the mediastinal lymph nodes; Bronchoalveolar lavage (BAL); Endobronchial forceps biopsy
University of Oxford - Recruiting 18 years to 55 years. - Phase I Trial to Evaluate the Safety and Immunogenicity of a ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy BCG Vaccinated Adults.
Sanofi - Recruiting 18 years to 55 years. - An Open-label, Non-randomized, Single Sequence, Two Periods, Four-treatment, Three Parallel Groups Pharmacokinetic Interaction Study of Repeated Oral Doses (Daily or Weekly Regimen) of Rifapentine on ATRIPLAT (Fixed Dose Combination of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate) Given to HIV+ Patients.
University of Oxford - Recruiting 18 years to 55 years. - A Phase I Randomised Trial to Evaluate the Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in Bacille Calmette-Gurin (BCG) Vaccinated Adults.
UCB, Inc. - Recruiting 18 years or older. - Observational Study to Evaluate the Safety and Effectiveness of Cimzia in Rheumatoid Arthritis and Crohn's Disease Patients When Using a Comprehensive Program of Tuberculosis Screening and Monitoring.
Active Sodium Phenylbutyrate and active cholecalciferol; Placebo Sodium Phenylbutyrate plus active cholecalciferol; Active Sodium Phenylbutyrate and placebo cholecalciferol; Placebo Sodium Phenylbutyrate plus placebo cholecalciferol
Zhejiang Beta Pharma Inc. - Recruiting 18 years to 75 years. - An Open-label, Randomized, Multicenter, Phase II Trial to Evaluate the Safety and Efficacy of Dose Escalation of Icotinib in Advanced or Metastatic NSCLC Patients After 8 Weeks Routine Therapy Evaluated as Stable Disease.
University of Cape Town - Recruiting 18 years or older. - A Randomized Controlled Trial to Evaluate the Impact of Using a Point-of-care Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients in Resource-poor Settings.
Singapore General Hospital - Recruiting 21 years or older. - Prospective Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection Treated at Singapore General Hospital.
Tuberculosis Research Centre, India - Recruiting 18 years or older. - A Randomized Controlled Clinical Trial Comparing Daily Vs. Intermittent 6 - Month Short Course Chemotherapy in Reducing Failures & Emergence of Acquired Rifampicin Resistance (ARR) in Patients With HIV and Pulmonary Tuberculosis.
Seoul National University Hospital - Recruiting 20 years or older. - The Impact of Vitamin D Level and Single Nucleotide Polymorphisms of Vitamin D Receptor Gene on the Development and Treatment Response of Tuberculosis.